New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.

RMD Open · 2025 · PMC12215137 · PMID 40592721

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Tocilizumab (TCZ), an IL-6 receptor antagonist, was studied in the FaSScinate and Focused trials, with trends towards improved mRSS that did not reach statistical significance for skin endpoints.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.